Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ACIU | 6-K | bullish | 6/10 | AC Immune reported positive week-100 safety and immunogenicity data from Part 1 of the VacSYn Phase 2 trial of ACI-7104 | Sep 23, 2026 |
| ANIP | PRESS-RELEASE | bullish | 6/10 | ANI Pharmaceuticals received FDA approval for its generic Everolimus Tablets for Oral Suspension (2mg, 3mg, 5mg), a gene | Sep 23, 2026 |
| CRDL | 6-K | bullish | 6/10 | Cardiol Therapeutics announced it achieved the original 110-patient enrollment target for its Phase III MAVERIC trial ah | Sep 23, 2026 |
| NSRX | 3 | neutral | 1/10 | Analysis based on filing metadata only, document content was unavailable. This is a Form 3 (initial statement of benefic | Sep 23, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis and partner Roche reported positive prespecified interim results from the Phase 3 IMAgINATION study of sefaxersen | Sep 23, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K furnishing a corporate presentation for September 2026. The filing contains no new mat | Sep 23, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca announced that the European Commission has approved Trixeo Aerosphere (budesonide/glycopyrronium/formoterol | Sep 23, 2026 |
| AUTL | EFFECT | neutral | 4/10 | The SEC declared effective Autolus Therapeutics' S-3 shelf registration (File No. 333-298910), filed 11 days earlier. Th | Sep 23, 2026 |
| SAFX | EFFECT | bearish | 7/10 | The SEC declared XCF Global's S-3 shelf registration (File No. 333-298839) effective on September 22, 2026. This allows | Sep 23, 2026 |
| NCEL | EFFECT | bearish | 5/10 | The SEC declared effective NewcelX Ltd.'s registration statement on Form S-3 (File No. 333-290516) under the 1933 Act, e | Sep 23, 2026 |
| APUS | 8-K | neutral | 3/10 | Apimeds Pharmaceuticals US, Inc. filed a Certificate of Amendment to effect a 1-for-10 reverse stock split, effective Ju | Sep 22, 2026 |
| VIR | COURT-RULING | neutral | 1/10 | The court granted a joint stipulation to extend discovery and motion deadlines in a pending employment-related lawsuit a | Sep 22, 2026 |
| NVO | COURT-RULING | neutral | 1/10 | This is a routine stipulated protective order entered in a patent litigation case between Novo Nordisk and Aios Inc. (Fe | Sep 22, 2026 |
| TWST | CLUSTER | bearish | 5/10 | CEO Emily Leproust executed a massive derivative exercise and open-market sale of ~$55M in TWST stock on September 17, 2 | Sep 22, 2026 |
| CSTL | CLUSTER | bearish | 4/10 | CEO Derek Maetzold and CCO Tobin Juvenal sold a combined $419K in open-market sales over a one-week window. The total re | Sep 22, 2026 |
| MLYS | CLUSTER | neutral | 3/10 | Two insiders at Mineralys Therapeutics sold a combined $295K in open-market transactions over a week. The sales are mode | Sep 22, 2026 |
| FDMT | CLUSTER | bearish | 4/10 | Two insiders at 4D Molecular Therapeutics sold a total of $833K in shares over a week, led by CEO David Kirn with $811K | Sep 22, 2026 |
| CYTK | CLUSTER | bearish | 5/10 | CEO Robert Blum sold $6.79M worth of CYTK shares in an open-market transaction, representing the vast majority of a $7.1 | Sep 22, 2026 |
| RVMD | CLUSTER | bearish | 4/10 | Seven insiders at Revolution Medicines, including the CFO, COO, and General Counsel, collectively sold approximately $7. | Sep 22, 2026 |
| HOWL | S-4 | bearish | 7/10 | Werewolf Therapeutics (HOWL) filed an S-4 registration statement for its merger with Ambros Therapeutics, where Ambros w | Sep 22, 2026 |
| TEVA | CLUSTER | bearish | 4/10 | Two Teva insiders sold a combined $14.53M in shares on September 18, 2026. Director Roberto Mignone accounted for the va | Sep 22, 2026 |
| CLDI | 8-K | bearish | 6/10 | Calidi Biotherapeutics entered into a stock purchase agreement for a registered direct offering of 1,025,640 shares at $ | Sep 22, 2026 |
| HELP | PRESS-RELEASE | neutral | 4/10 | Helus Pharma (HELP) reported Q1 2027 EPS of -$0.91, a 3.7% beat vs consensus of -$0.94, on zero revenue. The filing also | Sep 22, 2026 |
| NAMS | SC 13D/A | bullish | 5/10 | Frazier Life Sciences funds filed Amendment No. 7 to their Schedule 13D on NewAmsterdam Pharma, reporting open-market pu | Sep 22, 2026 |
| KRSA | 144 | neutral | 1/10 | Director Errol B. Desouza filed a Form 144 notice of intent to sell 100 shares of Korsana Biosciences common stock, with | Sep 22, 2026 |
| NBTX | PRESS-RELEASE | neutral | 1/10 | Nanobiotix S.A. disclosed its monthly share capital and voting rights as of August 31, 2026, reporting 50,941,528 shares | Sep 22, 2026 |
| BMEA | 424B5 | bearish | 6/10 | Biomea Fusion is conducting a dilutive underwritten public offering of common stock and pre-funded warrants at an undisc | Sep 22, 2026 |
| AYTU | 8-K | bullish | 6/10 | Aytu BioPharma reported fiscal Q4 2026 results with net revenue of $16.1M (+6.4% YoY), driven by $3.9M in EXXUA revenue | Sep 22, 2026 |
| BETRF | SC 13G | neutral | 4/10 | RA Capital Management, L.P. and affiliated entities disclosed a 9.0% passive stake in BetterLife Pharma Inc., holding 55 | Sep 22, 2026 |
| PULM | 425 | neutral | 3/10 | Eos SENOLYTIX announced its CEO will deliver a keynote at the 17th World Congress on Targeting Mitochondria (Oct 21-23, | Sep 22, 2026 |